Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 248 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GnRh (Leuprolide) Clear all
Active, not recruiting Phase 1 Interventional

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

NCT06305598
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 1 Interventional

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

NCT05617885
View directory record Official record
Conditions
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
Interventions
Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate, GNRH-A Goserelin, Degarelix
Drug
Lead sponsor
Praful Ravi, MB BCHir, MRCP
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 2 Interventional

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

NCT00063310
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Leuprolide acetate
Drug
Lead sponsor
Voyager Pharmaceutical Corporation
Industry
Eligibility
65 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Sun City, Arizona • Fort Lauderdale, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Insulin Resistance and Testosterone in Women

NCT00123110
View directory record Official record
Conditions
Insulin Resistance, Postmenopause
Interventions
metformin, leuprolide injection, placebo pill, placebo injection
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 79 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198
View directory record Official record
Conditions
Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
Interventions
Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Results available

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

NCT00451958
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg, Leuprolide 7.5 mg / Degarelix 160 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Homewood, Alabama • Laguna Hills, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

NCT02903368
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Leuprolide, Prednisone, Abiraterone Acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer

NCT01076335
View directory record Official record
Conditions
Prostate Cancer
Interventions
Neoadjuvant Hormonal Therapy, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 9, 2026, 12:16 PM EDT
Recruiting Phase 2Phase 3 Interventional

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

NCT04787744
View directory record Official record
Conditions
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
Procedure · Radiation · Other + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
20
States / cities
Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 9, 2026, 12:16 PM EDT
Active, not recruiting Phase 2 Interventional

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

NCT04569747
View directory record Official record
Conditions
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions
Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
Combination Product · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
32
States / cities
Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 4 Interventional Results available

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

NCT01161563
View directory record Official record
Conditions
Prostate Cancer
Interventions
Triptorelin pamoate, Leuprolide acetate
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
16
States / cities
Homewood, Alabama • Daytona Beach, Florida • Orange City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

NCT00598312
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate for Injectable Suspension
Drug
Lead sponsor
Oakwood Laboratories, LLC
Industry
Eligibility
45 Years and older · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Oakwood Village, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Degarelix in Patients With Prostate Cancer

NCT00928434
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
59
States / cities
Alexander City, Alabama • Homewood, Alabama • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 9, 2026, 12:16 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 9, 2026, 12:16 PM EDT
Recruiting No phase listed Observational

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT05567198
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Lupron Depot In The Treatment of Central Precocious Puberty

NCT00660010
View directory record Official record
Conditions
Puberty, Precocious
Interventions
Lupron (leuprolide acetate)
Drug
Lead sponsor
Abbott
Industry
Eligibility
Up to 10 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Oct 9, 2026, 12:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

NCT01163084
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
Interventions
Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 9, 2026, 12:16 PM EDT
Active, not recruiting Not applicable Interventional Results available

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

NCT05628363
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy
Device · Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

NCT01669291
View directory record Official record
Conditions
Fertility
Interventions
Bravelle and Menopur, Agonist, Antagonist
Drug
Lead sponsor
Main Line Fertility Center
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 9, 2026, 12:16 PM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

NCT01377389
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab, Leuprolide, Goserelin, Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 9, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Results available

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

NCT00903162
View directory record Official record
Conditions
Breast Cancer
Interventions
leuprolide, letrozole, zoledronic acid
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Denver, Colorado • Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 9, 2026, 12:16 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

NCT00430183
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, LHRH agonist, surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
221
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 9, 2026, 12:16 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

NCT00683917
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex 25 mg, Proellex 50 mg, Lupron Depot
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Sarasota, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 9, 2026, 12:16 PM EDT
Terminated Phase 4 Interventional

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

NCT01776203
View directory record Official record
Conditions
Dysfunctional Uterine Bleeding
Interventions
Medroxyprogesterone 17-Acetate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 9, 2026, 12:16 PM EDT